Genezen Alternatives & Competitors
6 companies similar to Genezen — Bringing Therapies to Life
Companies similar to Genezen
Excellos
A unique full-service CDMO, setting new standards in Cell & Gene Therapy
Batavia Biosciences
Accelerate Biotechnology
Cytovance Biologics
We are Cytovance Biologics, your responsive, reliable, and resourceful CDMO Partner.
Track all Genezen competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Rentschler Biopharma
Advancing medicine to save lives. Together.
FUJIFILM Biotechnologies
Partners for Life, Advancing Tomorrow's Medicines
About Genezen
Genezen, founded in 2014 in Indianapolis, IN, is a prominent player in the gene therapy CDMO industry. With a slogan of "Bringing Therapies to Life", the company leverages over a decade of experience to support the global cell and gene therapy manufacturing market. Genezen specializes in diverse vector modalities, incl...
Viral Vector Services, Plasmid Design and Manufacturing, Cell Therapy Development, Collaborative Project Management
Biotech Startups, Pharmaceutical Companies, Research Institutions, Biopharma Developers
Gene Therapy CDMO, Cell And Gene Therapy Manufacturing, Viral Vector Production, AAV Vector Work, Lentiviral Vector, Retroviral Vector, CGMP Manufacturing, Vector Modalities, Commercial Viral Vector Production, Regulatory Licensing, Process Development, Cell Banking, Assay Development, Viral Vector Testing, Clinical Trial Support
B2B, B2B2B
Service Fee, Project Based, Usage Based
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Genezen and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Genezen on 11 Mar 2026. The 6 companies listed here were last checked between 11 Sep 2024 and 14 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.